At a glance
- Originator Abbott Laboratories
- Class Anorectics; Oligopeptides
- Mechanism of Action Cholecystokinin A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 26 Feb 2001 No-Development-Reported for Obesity in USA (Unknown route)
- 13 Aug 1996 Preclinical development for Obesity in USA (Unknown route)